Patents by Inventor Dominic Man-Kit Lam
Dominic Man-Kit Lam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230263802Abstract: Methods of reducing incidence of or risk of developing a cerebral folate deficiency (CFD) or a CFD-related disorder comprising administering reduced folate compounds.Type: ApplicationFiled: July 27, 2021Publication date: August 24, 2023Inventors: George Ayoub, Dominic Man-Kit Lam
-
Publication number: 20210322540Abstract: Nucleic acid constructs for heterologous expression of a SARS-CoV-2 antigen on the surface of a yeast cell and related polypeptides, recombinant yeast cells, vaccine compositions, oral dosage formulations, and methods of inducing antigen-specific immune response to SARS-CoV-2.Type: ApplicationFiled: July 23, 2020Publication date: October 21, 2021Inventors: Dominic Man-Kit Lam, Jie Liu
-
Publication number: 20210324392Abstract: Nucleic acid constructs for heterologous expression of a SARS-CoV-2 antigen on the surface of a yeast cell and related polypeptides, recombinant yeast cells, vaccine compositions, oral dosage formulations, and methods of inducing antigen-specific immune response to SARS-CoV-2.Type: ApplicationFiled: August 17, 2020Publication date: October 21, 2021Inventors: Dominic Man-Kit Lam, Jie Liu
-
Patent number: 11103571Abstract: In the invention described here, the approach is to formulate an edible vaccine based on N-terminal yeast surface display expression systems including S. cerevisiae EBY100/pYD5-VP28, S. cerevisiae EBY100/pYD5-VP28-VP24 and S. cerevisiae EBY100/pYD5-VP24 for preventing shrimps such as L. vannamei, P. monodon and M. rosenbergii species from white spot syndrome virus (WSSV) infection, suggesting that yeast surface display expression system expressing WSSV antigen has potential as a prophylactic treatment for WSSV in shrimps via oral vaccination. The technology developed in this patent application can also be used to produce edible (oral) vaccines for preventing and treating other infectious diseases in animals and human.Type: GrantFiled: April 13, 2020Date of Patent: August 31, 2021Inventors: Olivia Yee-Yee Lam, Dominic Man-Kit Lam, Han Lei, Fong Wilson Lam
-
Publication number: 20200353066Abstract: In the invention described here, the approach is to formulate an edible vaccine based on N-terminal yeast surface display expression systems including S. cerevisiae EBY100/pYD5-VP28, S. cerevisiae EBY100/pYD5-VP28-VP24 and S. cerevisiae EBY100/pYD5-VP24 for preventing shrimps such as L. vannamei, P. monodon and M. rosenbergii species from white spot syndrome virus (WSSV) infection, suggesting that yeast surface display expression system expressing WSSV antigen has potential as a prophylactic treatment for WSSV in shrimps via oral vaccination. The technology developed in this patent application can also be used to produce edible (oral) vaccines for preventing and treating other infectious diseases in animals and human.Type: ApplicationFiled: April 13, 2020Publication date: November 12, 2020Applicant: POLY TECH SERVICES LIMITEDInventors: Olivia Yee-Yee Lam, Dominic Man-Kit Lam, Han Lei, Fong Wilson Lam
-
Patent number: 10793866Abstract: In the invention described here, the approach is to formulate an edible vaccine based on N-terminal yeast surface display expression platform that producing S.cerevisiae EBY100/pYD5-preS2/S(adw) and S.cerevisiae EBY100/pYD5-preS2/S(adr) for protecting and treating human against hepatitis B virus (HBV) infection, suggesting that yeast surface display expression system expressing HBsAg antigen has potential as a prophylactic treatment for HBV in human via oral vaccination. The technology developed in this patent application can also be used to produce edible (oral) vaccines for preventing and treating other infectious diseases in human.Type: GrantFiled: March 27, 2018Date of Patent: October 6, 2020Assignee: DrD LifeSciences Group LimitedInventors: Dominic Man-Kit Lam, Olivia Yee-Yee Lam, Han Lei
-
Patent number: 10617751Abstract: In the invention described here, the approach is to formulate an edible vaccine based on N-terminal yeast surface display expression systems including S. cerevisiae EBY100/pYD5-VP28, S. cerevisiae EBY100/pYD5-VP28-VP24 and S. cerevisiae EBY100/pYD5-VP24 for preventing shrimps such as L. vannamei, P. monodon and M. rosenbergii species from white spot syndrome virus (WSSV) infection, suggesting that yeast surface display expression system expressing WSSV antigen has potential as a prophylactic treatment for WSSV in shrimps via oral vaccination. The technology developed in this patent application can also be used to produce edible (oral) vaccines for preventing and treating other infectious diseases in animals and human.Type: GrantFiled: July 13, 2017Date of Patent: April 14, 2020Assignee: VisionTech International LimitedInventors: Olivia Yee-Yee Lam, Dominic Man-Kit Lam, Han Lei, Fong Wilson Lam
-
Publication number: 20190300887Abstract: In the invention described here, the approach is to formulate an edible vaccine based on N-terminal yeast surface display expression platform that producing S.cerevisiae EBY100/pYD5-preS2/S(adw) and S.cerevisiae EBY100/pYD5-preS2/S(adr) for protecting and treating human against hepatitis B virus (HBV) infection, suggesting that yeast surface display expression system expressing HBsAg antigen has potential as a prophylactic treatment for HBV in human via oral vaccination. The technology developed in this patent application can also be used to produce edible (oral) vaccines for preventing and treating other infectious diseases in human.Type: ApplicationFiled: March 27, 2018Publication date: October 3, 2019Applicant: International Biotech Institute, Inc.Inventors: Dominic Man-Kit Lam, Olivia Yee-Yee Lam, Han Lei
-
Publication number: 20190298817Abstract: In the invention described here, the approach is to formulate an edible vaccine based on N-terminal yeast surface display expression systems including S. cerevisiae EBY100/pYD5-VP28, S. cerevisiae EBY100/pYD5-VP28-VP24 and S. cerevisiae EBY100/pYD5-VP24 for preventing shrimps such as L. vannamei, P. monodon and M. rosenbergii species from white spot syndrome virus (WSSV) infection, suggesting that yeast surface display expression system expressing WSSV antigen has potential as a prophylactic treatment for WSSV in shrimps via oral vaccination. The technology developed in this patent application can also be used to produce edible (oral) vaccines for preventing and treating other infectious diseases in animals and human.Type: ApplicationFiled: July 13, 2017Publication date: October 3, 2019Applicant: POLY TECH SERVICES LIMITEDInventors: Olivia Yee-Yee Lam, Dominic Man-Kit Lam, Han Lei, Fong Wilson Lam
-
Publication number: 20130004547Abstract: The invention provides for anti-pathogen vaccines produced in recombinant bacteria and/or transgenic plants and administered through standard vaccine introduction methods or oral administration. In one embodiment, the vaccine is administered through the consumption of the edible plant as food, or the bacteria administered orally. The present invention also provides a method of using genetically modified microorganisms, such as lactic acid bacteria, including Lactococcus lactis strains, as oral vaccines. In one embodiment, Lactococcus lactis expressing the avian influenza HA gene can be used as an oral vaccine for protection against H5N1 virus infection. In another embodiment, said Lactococcus lactis is administered as an oral vaccine in conjunction with an adjuvant such as cholera toxin B.Type: ApplicationFiled: June 22, 2012Publication date: January 3, 2013Applicant: VAXGENE CORPORATIONInventors: Dominic Man-Kit LAM, Yuhong XU
-
Publication number: 20120276167Abstract: In one embodiment, the present invention provides for an edible mini-capsule form of live, non-persisting, recombinant Lactococcus lactis (L. lactis) vaccine against a pathogen such as the highly virulent influenza H5N1 strain. Enteric coated capsule of the present invention induced high levels of hemagglutinin-specific serum IgG and fecal IgA antibody production after oral administration in mice and chickens, and rendered complete protection against a lethal challenge of H5N1 virus in mice. The present invention thus demonstrates a broadly applicable platform technology for producing and administering edible vaccines against bacterial and viral infections.Type: ApplicationFiled: December 23, 2010Publication date: November 1, 2012Applicant: VAXGENE CORPORATIONInventors: Dominic Man-Kit Lam, Yuhong Xu
-
Publication number: 20120171230Abstract: The anti-pathogen vaccine of the present invention is produced in recombinant bacteria and/or transgenic plants and then administered through standard vaccine introduction method or through the oral administration. A DNA sequence encoding for the expression of an antigen of a pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a bacterial or transgenic plant. Preferably, a foreign gene is expressed in a portion of the plant or bacteria, and all or part of the antigen expressing plant or bacteria used for vaccine administration. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, or the bacteria administered orally. The present invention also provides a method of using genetically modified microorganisms generally recognized to be edible and/or harmless to animals or humans when ingested, such as lactic acid bacteria, including Lactococcus lactis strains, as oral vaccines.Type: ApplicationFiled: July 13, 2010Publication date: July 5, 2012Applicant: VAXGENE CORPORATIONInventors: Dominic Man-Kit Lam, Yuhong Xu
-
Patent number: 7504560Abstract: The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expression of a surface antigen of a viral pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a transgenic plant. This gene is then transferred to plant cells using a procedure that results in its integration into the plant genome, such as through the use of an Agrobacterium tumenfaciens plasmid vector system. Preferably, the foreign gene is expressed in an portion of the plant that is edible by humans or animals. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, preferably in the form of a fruit or vegetable juice which can be taken orally.Type: GrantFiled: May 12, 2005Date of Patent: March 17, 2009Assignee: Prodigene, Inc.Inventors: Charles Joel Arntzen, Dominic Man-Kit Lam
-
Publication number: 20040166121Abstract: The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expression of a surface antigen of a viral pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a transgenic plant. This gene is then transferred to plant cells using a procedure that results in its integration into the plant genome, such as through the use of an Agrobacterium tumenfaciens plasmid vector system. Preferably, the foreign gene is expressed in an portion of the plant that is edible by humans or animals. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, preferably in the form of a fruit or vegetable juice which can be taken orally.Type: ApplicationFiled: December 11, 2003Publication date: August 26, 2004Inventors: Charles Joel Arntzen, Dominic Man-Kit Lam
-
Publication number: 20030138456Abstract: The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expression of a surface antigen of a viral pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a transgenic plant. This gene is then transferred to plant cells using a procedure that results in its integration into the plant genome, such as through the use of an Agrobacterium tumenfaciens plasmid vector system. Preferably, the foreign gene is expressed in an portion of the plant that is edible by humans or animals. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, preferably in the form of a fruit or vegetable juice which can be taken orally.Type: ApplicationFiled: July 31, 2001Publication date: July 24, 2003Inventors: Charles Joel Arntzen, Dominic Man-Kit Lam
-
Publication number: 20020006411Abstract: The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expression of a surface antigen of a viral pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a transgenic plant. This gene is then transferred to plant cells using a procedure that results in its integration into the plant genome, such as through the use of an Agrobacterium tumenfaciens plasmid vector system. Preferably, the foreign gene is expressed in an portion of the plant that is edible by humans or animals. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, preferably in the form of a fruit or vegetable juice which can be taken orally.Type: ApplicationFiled: August 9, 2001Publication date: January 17, 2002Inventors: Charles Joel Arntzen, Dominic Man-Kit Lam
-
Publication number: 20010053367Abstract: The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expression of a surface antigen of a viral pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a transgenic plant. This gene is then transferred to plant cells using a procedure that results in its integration into the plant genome, such as through the use of an Agrobacterium tumenfaciens plasmid vector system. Preferably, the foreign gene is expressed in an portion of the plant that is edible by humans or animals. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, preferably in the form of a fruit or vegetable juice which can be taken orally.Type: ApplicationFiled: March 23, 2001Publication date: December 20, 2001Applicant: PRODIGENE, INC.Inventors: Charles Joel Arntzen, Dominic Man-Kit Lam
-
Patent number: 6136320Abstract: The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expression of a surface antigen of a viral pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a transgenic plant. This gene is then transferred to plant cells using a procedure that results in its integration into the plant genome, such as through the use of an Agrobacterium tumenfaciens plasmid vector system. Preferably, the foreign gene is expressed in an portion of the plant that is edible by humans or animals. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, preferably in the form of a fruit or vegetable juice which can be taken orally.Type: GrantFiled: July 7, 1998Date of Patent: October 24, 2000Assignee: Prodigene, Inc.Inventors: Charles Joel Arntzen, Dominic Man-Kit Lam
-
Patent number: 6034298Abstract: The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expression of a surface antigen of a viral pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a transgenic plant. This gene is then transferred to plant cells using a procedure that results in its integration into the plant genome, such as through the use of an Agrobacterium tumefaciens plasmid vector system. Preferably, the foreign gene is expressed in a portion of the plant that is edible by humans or animals. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, preferably in the form of a fruit or vegetable juice which can be taken orally.Type: GrantFiled: August 23, 1996Date of Patent: March 7, 2000Assignee: Prodigene, Inc.Inventors: Dominic Man-Kit Lam, Charles Joel Arntzen, Hugh Stanley Mason
-
Patent number: 5914123Abstract: The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expression of a surface antigen of a viral pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a transgenic plant. This gene is then transferred to plant cells using a procedure that results in its integration into the plant genome, such as through the use of an Agrobacterium tumefaciens plasmid vector system. Preferably, the foreign gene is expressed in an portion of the plant that is edible by humans or animals. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, preferably in the form of a fruit or vegetable juice.Type: GrantFiled: June 7, 1995Date of Patent: June 22, 1999Assignee: Prodigene, Inc.Inventors: Charles Joel Arntzen, Dominic Man-Kit Lam